KZA 2.02% $1.22 kazia therapeutics limited

recent investment report for novogen, page-2

  1. 3,567 Posts.
    re: recent investment report for novogen attn gerr Gerry, are you around?

    What are your thoughts on the projections in this report. Looks conservative given they have done the numbers on only two cancer types and assumed a profit margin of 10% (compared to royalty rates up to 40% for similar drugs), a cost of $10000 p.a. (compared to other anti-cancer drugs charging much more) and didn't take into account any large one off payment in a licence deal. This payment could be quite significant when compared to payments to Imclone for it's Erbitux drug of $2bn approx $20/share for Novogen.

    Anyhow, good to see analysts finally seeing the potential in novogen i.e. the best drug of it's kind out there and a low market cap.
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap ! $164.3M
Open High Low Value Volume
$1.25 $1.25 $1.20 $68.10K 55.82K

Buyers (Bids)

No. Vol. Price($)
3 1394 $1.21

Sellers (Offers)

Price($) Vol. No.
$1.22 325 1
View Market Depth
Last trade - 15.32pm 04/08/2021 (20 minute delay) ?
-0.025 ( 2.83 %)
Open High Low Volume
$1.23 $1.25 $1.20 14641
Last updated 15.28pm 04/08/2021 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.